BFM
NERV icon

Boothbay Fund Management’s Minerva Neurosciences NERV Stock Holding History

Boothbay Fund Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,508
Closed -$169K – 1066
2020
Q1 		$169K Buy
3,508
+1,435
+69% +$86.6K 0.01% 679
2019
Q4 		$118K Buy
+2,073
New +$91.4K 0.01% 746

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's NERV Position: Q2 2020 in Review

Boothbay Fund Management sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 3,508 shares — an estimated $169K sold.

Boothbay Fund Management first reported a position in NERV in Q4 2019 and held it in 2 quarters. The position peaked at $169K in Q1 2020. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Boothbay Fund Management reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 3,508 Minerva Neurosciences shares in Q2 2020, an estimated $169K.
  • Boothbay Fund Management first reported a position in Minerva Neurosciences in Q4 2019 and held it in 2 quarters.
  • Boothbay Fund Management's Minerva Neurosciences position peaked at $169K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Boothbay Fund Management's 13F filing for Q2 2020, filed 14 Aug 2020.